Zalutumumab

立即咨询

Zalutumumab

本产品不向个人销售，仅用作科学研究，不用于任何人体实验及非科研性质的动物实验。

CAS NO:

667901-13-5

Zalutumumab 是一种高亲和力的纯人类 IgG1 单克隆抗体，靶向EGFR。Zalutumumab 与表皮生长因子受体的结构域 III 结合，通过阻断表皮生长因子的结合和干扰受体的活性构象发挥作用。Zalutumumab 与 IgG 及其 Fab 区段的EC₅₀值分别为 7 和 19 nM。Zalutumumab 可用于癌症的研究。

生物活性

Zalutumumab is a high affinity, completely humanIgG1monoclonal antibody targetingEGFR. Zalutumumab binds to domain III of theEGFreceptor and acts by blocking the binding ofEGFand by sterically interfering with the active conformation of the receptor. Zalutumumab binds withIgGand its Fab fragment withEC₅₀s of 7 and 19 nM, respectively. Zalutumumab can be used for the research ofcancer^[1]^[2]^[3].

体外研究
(In Vitro)

Zalutumumab (0-1 μM; 60 min) effectively blocks EGF-induced EGFR activation with an IC₅₀value of 1.3 nM^[2].
Zalutumumab (0-1 μM; 96 h) affects proliferation of A431 cells^[2].
Zalutumumab (10 μg/mL; 24 h) induces a comparable percentage of specificlysis of A431 cells with mouse macrophages^[3].

Cell Proliferation Assay^[2]

Cell Line:	A431 cell line
Concentration:	0-1 μM
Incubation Time:	96 hours
Result:	Inhibited A431 cells proliferation with an IC₅₀value of 1.5 nM.

体内研究
(In Vivo)

Zalutumumab (5 mg/kg; i.p. 2 h after tumor induction) affects tumor growth in A431 xenograft models^[3].
Zalutumumab (0.5 and 5 mg/kg; i.p. once ) delays tumor growth when mice with tumor volumes of 80-100 mm³^[3].

Animal Model:	SCID mice with A431 cells injection^[3]
Dosage:	5 mg/kg
Administration:	Intraperitoneal injection; 5 mg/kg 2 hours after tumor induction
Result:	Effectively inhibited tumor growth in A431 xenograft models with an early treatment.

Clinical Trial

CAS 号

667901-13-5

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.